Terms of Access and Use

By downloading, accessing, or viewing material from this website, you agree to the following Terms of Use. The research and analysis provided by Forensic Alpha Limited (“we”, “us”) is for informational and educational purposes only and does not constitute investment advice, a recommendation to buy, sell, or hold any security, or any other form of regulated advice. We do not have, and do not seek to establish, any position (long or short) in the securities discussed in our research.

Our reports present our independent opinions on publicly available information, including but not limited to, company disclosures and financial statements. We aim to highlight potential risks, governance issues, or accounting practices that we believe merit further consideration by market participants. You agree to conduct your own research and due diligence, and to consult your own financial, legal, tax, and other professional advisers before making any investment or business decision. Use of our research is entirely at your own risk. In no event shall Forensic Alpha Limited or any affiliated party be liable for any direct, indirect, incidental, or consequential losses arising from your use of our materials.

The information we provide is based on sources we believe to be accurate and reliable at the time of publication, but it is provided “as is” without any representation or warranty of any kind, whether express or implied, including without limitation as to accuracy, completeness, or fitness for any particular purpose. All opinions expressed are subject to change without notice, and we do not undertake to update or supplement our research.

Access to our research is intended only for persons who are professional investors, institutional investors, or otherwise qualified to receive such information under applicable laws in their jurisdiction. In the United Kingdom, this includes (but is not limited to) persons falling within one or more of the categories described in Articles 19 (Investment Professionals) and 49 (High Net Worth Companies, Unincorporated Associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. By proceeding to access our materials, you confirm that you meet the relevant criteria in your jurisdiction and are legally permitted to receive such information.

All content on this site is the intellectual property of Forensic Alpha Limited and is protected by applicable copyright laws. You agree not to reproduce, distribute, or transmit our research, in whole or in part, without our prior written consent, except by sharing a direct link to our website.

By clicking “I Agree” below, you confirm that you have read and agree to Forensic Alpha Limited’s Terms of Access and Use, that you are a professional or institutional investor (or otherwise qualified under the laws of your jurisdiction to receive such information), and that you understand our research does not constitute investment advice or a recommendation to buy, sell, or hold any security.
I Agree
back arrow

Commvault Systems: Locking Down Numbers

Thomas Beevers
Thomas Beevers
May 20, 2026
Copied!
share button icon

Commvault Systems: Locking Down Numbers

Commvault released Q3 earnings on Tuesday. While the numbers themselves were strong, the market was disappointed with the level of net new ARR achieved in the quarter. The perceived shift was taken badly and the stock plummeted. Meanwhile, and separate to this dynamic, our system has identified a growing number of red flags from the 10-Q filing as our risk rating moves from a '7' to a '10'. The key driver of this change was DSO, which has risen to a five-year high of 105 days on our calculation (see chart below).

Looking closer at the 10-Q we can see that "Accounts Receivable" has increased by 42% in the past 9 months. Almost all of this movement has occurred in the latest quarter.  In addition we see a similar increase in “Unbilled Receivables” (see extract from disclosure below), a line item which represents revenue recognized but not yet billed to the customer.

Combined, billed and unbilled receivables now represent over $400m. This makes it the second largest item on the balance sheet (after cash) and the equivalent of 118 days of sales. That’s a huge amount of revenue that’s already been recognized in the income statement, but which has not yet converted into cash.

Management was asked directly about elevated DSO on the call and the Cheif Accounting Officer put it down to the fact that Q3 (being the end of the calendar year)  tends to see more deals being signed at the end of the quarter.

“...one of the things we saw this quarter, and it’s not uncommon in Q3, I’ll be honest. Q3 has a tendency to be one of our most pressured free cash flow quarters. And it’s really just because of the way the sales cycles work with the calendar year-end, we have a tendency to see more deals close in the last few weeks of the quarter and this quarter was no exception to that. I can tell you, over 60% of our deals actually closed in the last few weeks of the quarter.”

Danielle Abrahamsen, Chief Accounting Officer

While this explains why DSO is higher than in Q4, it doesn’t explain why DSO is significantly higher compared to Q3 24 and Q3 25.

Sharply rising DSO can mean a number of things, including timing issues or weak collection. But it is often viewed as a red flag due to its association with aggressive revenue recognition. This is particularly the case where it’s accompanied by a rise in “unbilled receivables” as observed here. Since unbilled receivables are based on calculations and estimates of amounts due, it can be a powerful lever in accelerating revenue recognition.

In this case we also see that a significant proportion of this unbilled balance (nearly 50%) is classified as “long-term”, implying that the revenue recognized is not expected to translate to cash for over 12 months.  One interesting disclosure in the notes to the accounts (extract below) suggests that this balance may be connected to providing extended credit terms to customers. Such tactics can help stimulate sales (at least in the short run) but elevates collection risk and hurts cash flow.

A second important flag is the increasing value of “Deferred Commissions”, which represents sales commissions paid to employees, but capitalized on the balance sheet rather than expensed.  This is allowable per US Gaap, but a sharp increase can suggest aggressive capitalization.  The filings show this balance has risen by 40% YoY from $68m in Q3 24 to $95m in Q3 25.  While we would expect deferred commissions to increase broadly in line with activity, in this case, we can see it has risen much faster than sales.

The expansion of the balance sheet has weighed on cash flow this year and contributed to its weakness.  The impact of growing receivables alone has had an impact of $100m in the 9 month period, as we can see in the extract of the statutory cash flow statement from the 10-Q (see below). Note that the impact has been partially mitigated, thanks only to the increase in “deferred revenue”, which is likely a function of a growing SAAS business (where the client typically pays up front).

Investors who have been following Commvault for some time will know that the CFO role has seen an unusual amount of churn in recent years. After longstanding CFO Brian Carolan resigned in July 2022, he was replaced by Gary Merrill, who was then reassigned as CCO 2 years later, in August 2024. His replacement, Jen DiRico lasted only 16 months, resigning in December 2025. This has left the company with no CFO while the company searches for a replacement. While this level of churn in itself doesn’t imply an issue with the books, when combined with a number of red flags in the filings, it certainly warrants a heightened level of caution.

If you are an institutional investor, you can sign up to our email list here
arrow icon
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Institutional investors are eligible for a 7-day free trial.

Our machine intelligence helps Portfolio Managers to spot critical red flags hidden deep within the financial statements and governance disclosures.

Request Demo

Forensic Alpha uses proprietary machine intelligence to identify risks hidden deep within the financial statements and governance disclosures.

Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB

Forensic Alpha US INC
12 East 49th Street
New York
NY 10017
USA

forensic alpha
Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB
Forensic Alpha US INC
12 East 49th Street
New York NY 10017
USA
Forensic Alpha Limited is authorised and regulated by the Financial Conduct Authority (Reference number: 763770)
© 2022 Forensic Alpha. All rights reserved.  Terms & Conditions  |  Privacy Policy  |  Cookie policy
twitter profilelinkedin profile